Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Japan’s 1st Rituxan Biosimilar to Hit Shelves as Scheduled despite Patent Suit Filed
Kyowa Hakko Kirin is planning to launch Japan’s first Rituxan (rituximab) biosimilar, manufactured by Sandoz, on January 18 as scheduled despite the filing of a patent infringement suit by Genentech late last month, according to material from the Japanese company…
To read the full story
Related Article
- Tokyo Court Dismisses Genentech’s Bid to Block Rituxan Biosimilar
May 30, 2019
- Japan’s 1st Rituxan Biosimilar Boasts 13% Share: Sandoz Country Head
June 28, 2018
- Kyowa Kirin Officially Announces Launch of Japan’s 1st Rituxan Biosimilar on Jan. 18
January 18, 2018
- Genentech Seeks to Block Rituxan Biosimilar Launch in Japan
January 10, 2018
- Japan’s 1st Rituxan Biosimilar to Arrive Soon, Sandoz Confident on Market Acquisition
November 29, 2017
- Japan Approves 1st Rituxan Biosimilar from Sandoz
September 28, 2017
BUSINESS
- Takeda Hands CEO Baton to Kim after 12-Year Weber Era
June 25, 2026
- Tanabe Starts Long-Term Uplizna Study in IgG4-Related Disease
June 25, 2026
- ASKA Shareholders Back Faster Poison Pill Activation
June 25, 2026
- EU Approves Padcev-Keytruda for Earlier Bladder Cancer Use
June 25, 2026
- Tacrolimus Generics Add Cell Transplantation Indication
June 25, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…